Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01028768
Recruitment Status : Completed
First Posted : December 9, 2009
Last Update Posted : May 7, 2012
NPS Pharma
Information provided by:

Brief Summary:

To evaluate the effect of renal impairment on the pharmacokinetics (PK) of teduglutide following subcutaneous (SC) administration of 10 mg teduglutide.

Secondary objectives are to assess the safety and tolerability of 10 mg teduglutide. A further objective is the description of the PK of teduglutide following SC administration of 10 mg teduglutide in elderly (≥ 65 years) healthy subjects compared to non elderly healthy subjects.

Condition or disease Intervention/treatment Phase
Renal Impairment Drug: Teduglutide Phase 1

Detailed Description:
Pharmacokinetic study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Open Label Pharmacokinetic (PK) Study, Conducted at One Investigational Site in Germany, to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Teduglutide Following Subcutaneous Administration of 10 mg Teduglutide and to Evaluate Safety and Tolerability of 10 mg Teduglutide
Study Start Date : October 2009
Primary Completion Date : January 2010
Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Teduglutide
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Teduglutide Drug: Teduglutide
10 mg, one-time subcutaneous

Primary Outcome Measures :
  1. Pharmacokinetics of teduglutide [ Time Frame: 24 hrs ]

Secondary Outcome Measures :
  1. Safety and tolerability of 10 mg teduglutide (assessed by physical examination, vital signs, clinical laboratory, electrocardiogram [ECG] and adverse events [AE]) [ Time Frame: 7 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with moderate, severe and end stage renal failure and matched healthy controls.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01028768

Nycomed GmbH
Konstanz, Germany, 78467
Sponsors and Collaborators
NPS Pharma

Responsible Party: Head of Exploratory Clinical Development, Nycomed GmbH Identifier: NCT01028768     History of Changes
Other Study ID Numbers: TE-1777-101-EC
First Posted: December 9, 2009    Key Record Dates
Last Update Posted: May 7, 2012
Last Verified: April 2010

Keywords provided by Nycomed:
Renal impairment
Renal impairment study

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases